Antifungal Pretreatment May Worsen Outcomes in Fungal Keratitis Patients

This article originally appeared here.
 Pretreatment associated with significantly worse 3-month visual acuity
Pretreatment associated with significantly worse 3-month visual acuity

(HealthDay News)— Fungal keratitis patients pretreated with antifungal medication appear to have worse outcomes, according to a study published online June 21 in Clinical & Experimental Ophthalmology.

Catherine Q. Sun, M.D., from the University of California, San Francisco, and colleagues conducted a randomized , double-blind trial to determine the optimal treatment for filamentous fungal keratitis. Patients at the Aravind Eye Care System in India were randomized to treatment with either topical natamycin or voriconazole.

Related Articles

The researchers found that 44 percent of the 323 patients enrolled presented on an antifungal agent. Larger mean baseline infiltrate size and epithelial defect size were seen in pretreated patients. Pretreatment was associated with significantly worse three-month visual acuity, larger three-month scar size, and increased odds of corneal perforation and/or transplant in multivariate analysis.

"Fungal keratitis that is smear-positive despite being pretreated with appropriate antifungal agents appears to be a risk factor for worse outcomes, likely due to initial ulcer severity and treatment failure," conclude the authors.

The drugs used in the study were donated by Alcon and Pfizer.

Abstract
Full Text (subscription or payment may be required)

Loading links....